J&J To Pay States $181M Over Deceptive Risperdal Marketing
Johnson & Johnson agreed Thursday to pay $181 million to 36 states and Washington, D.C., to resolve claims that it deceptively marketed its antipsychotic drugs Risperdal and Invega in what the...To view the full article, register now.
Already a subscriber? Click here to view full article